1. Home
  2. NVCR vs PENN Comparison

NVCR vs PENN Comparison

Compare NVCR & PENN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • PENN
  • Stock Information
  • Founded
  • NVCR 2000
  • PENN 1972
  • Country
  • NVCR Switzerland
  • PENN United States
  • Employees
  • NVCR N/A
  • PENN N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • PENN Hotels/Resorts
  • Sector
  • NVCR Health Care
  • PENN Consumer Discretionary
  • Exchange
  • NVCR Nasdaq
  • PENN Nasdaq
  • Market Cap
  • NVCR 1.9B
  • PENN N/A
  • IPO Year
  • NVCR 2015
  • PENN 1994
  • Fundamental
  • Price
  • NVCR $17.50
  • PENN $15.73
  • Analyst Decision
  • NVCR Buy
  • PENN Buy
  • Analyst Count
  • NVCR 6
  • PENN 20
  • Target Price
  • NVCR $32.83
  • PENN $22.63
  • AVG Volume (30 Days)
  • NVCR 861.0K
  • PENN 3.7M
  • Earning Date
  • NVCR 04-24-2025
  • PENN 05-08-2025
  • Dividend Yield
  • NVCR N/A
  • PENN N/A
  • EPS Growth
  • NVCR N/A
  • PENN N/A
  • EPS
  • NVCR N/A
  • PENN N/A
  • Revenue
  • NVCR $621,711,000.00
  • PENN $6,643,700,000.00
  • Revenue This Year
  • NVCR $2.90
  • PENN $8.60
  • Revenue Next Year
  • NVCR $10.47
  • PENN $5.24
  • P/E Ratio
  • NVCR N/A
  • PENN N/A
  • Revenue Growth
  • NVCR 18.27
  • PENN 5.51
  • 52 Week Low
  • NVCR $14.17
  • PENN $13.25
  • 52 Week High
  • NVCR $34.13
  • PENN $23.08
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 50.16
  • PENN 48.35
  • Support Level
  • NVCR $16.19
  • PENN $14.85
  • Resistance Level
  • NVCR $17.70
  • PENN $16.01
  • Average True Range (ATR)
  • NVCR 0.83
  • PENN 0.66
  • MACD
  • NVCR 0.07
  • PENN 0.14
  • Stochastic Oscillator
  • NVCR 50.69
  • PENN 61.41

About NVCR NovoCure Limited

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Share on Social Networks: